Creative Biolabs Updated a Full Set of Probiotic Strains to Meet Market Demand
New York, USA – September 28, 2022 – A recent study on male mice, published in Frontier in Neuroscience, revealed significant increases in gut Akkermansia muciniphila and Bifidobacterium bacteria strains following oral administration of Lactobacillus paragasseri, which can reduce the symptoms of depression. It is well-known that probiotics can tip the balance back to good bacteria, boost the immunity of individuals, fight inflammation, and provide relief for painful digestion related to irritable bowel syndrome (IBS) or infectious diarrhea. More importantly, some gut bacteria are expected to emerge as potential sources of novel therapeutics. This indicates that next-generation probiotics (NGPs) may break the limitation boundary not only to serve as traditional probiotics in foods or dietary supplements but are also defined as organisms for pharmaceutical application development.
Creative Biolabs has spent years developing probiotic strains to handle specific needs and issues of customers and can provide different probiotic strains, customized small-scale probiotic powder, and fermentation liquid products to support customers’ research needs. Probiotic strains include but are not limited to Escherichia, Akkermansia, and Christensenella.
Although Escherichia is a commensal organism in the human intestine, pathogenic Escherichia causes a variety of diseases. Three major illnesses that are caused by pathogenic Escherichia coli in humans are urinary tract infection (UTI), blood and central nervous system infections, and gastroenteric disease.
As a prominent developer of probiotic strains, Creative Biolabs can provide researchers with E. coli Nissle 1917 for probiotic experiments. Escherichia coli Nissle 1917 is a probiotic strain with proven efficacy in inducing and maintaining remission of ulcerative colitis, which has been used as a probiotic and therapeutic agent for over a century.
Currently, diverse research on Akkermansia muciniphila mainly focuses on explaining its relationship with diseases. Akkermansia is a next-generation beneficial strain that is essential for gut health and has demonstrated promising effects in becoming a therapeutic target for microbiota-related illnesses such as colitis, metabolic syndrome, autoimmune diseases, and cancer.
Based on its extensive experience in dealing with probiotic strains, Creative Biolabs provides probiotic products, including but not limited to:
* Akkermansia muciniphila Muc
* Akkermansia muciniphila YL44
* Akkermansia muciniphila Derrien et al.
* Akkermansia muciniphila
Research and development of therapeutic applications for Christensenella are highly active right now. As live biotherapeutic products, Christensenella bacteria have wide therapeutic utilities for the treatment of obesity and related metabolic disorders. In addition, researchers could explore its relevance to other diseases with a more profound understanding of Christensenella’s role in the gut microbiome. With extensive experience in probiotic strain development, Creative Biolabs provides three Christensenella strains, including but not limited to:
* Christensenella minuta
* Christensenella massiliensis
* Christensenella timonensis
To learn more about probiotic strain products at Creative Biolabs, please visit https://live-biotherapeutic.creative-biolabs.com.
About Creative Biolabs
With years of experience in the development and production of probiotic strains, Creative Biolabs offers high-quality probiotic strains with fulfilling and perfect customer service.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://live-biotherapeutic.creative-biolabs.com
